X Xie1, S Sinha1, Z Yi1,2, P R Langlais1, M Madan1, B P Bowen1, W Willis1, C Meyer1,3. 1. Center for Metabolic Biology, Arizona State University, Tempe, AZ, USA. 2. Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy/Health Sciences, Wayne State University, Detroit, MI, USA. 3. Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, FL, USA.
Abstract
BACKGROUND/ OBJECTIVES: To gain further insight into the role of adipocyte mitochondria in systemic lipid metabolism, inflammation and insulin sensitivity in humans and to provide a better understanding of the mechanisms of action of the peroxisome proliferator-activated receptor gamma agonist pioglitazone. SUBJECTS/ METHODS: Mitochondrial DNA (mtDNA) copy number, mitochondrial distribution, mitochondrial and overall cellular protein abundances as well as intrinsic mitochondrial function of subcutaneous adipocytes were assessed by real-time quantitative PCR, MitoTracker staining, global proteomics analyses and NADH cytochrome c reductase activity in insulin-sensitive, normal-glucose-tolerant (NGT) individuals and age, gender, adiposity-matched insulin-resistant individuals with abnormal glucose tolerant (AGT) before and after 3 months of pioglitazone treatment. RESULTS: mtDNA copy number/adipocyte and mtDNA copy number/adipocyte volume were ~55% and ~4-fold lower in AGT than in NGT, respectively, and correlated positively with the M-value of euglycemic clamps and high-density lipoprotein, and negatively with fasting plasma triglyceride, tumor necrosis factor-α and interleukin-6 levels in the entire cohort. mtDNA copy number/adipocyte volume also correlated positively with plasma adiponectin. Pioglitazone, which improved insulin sensitivity, plasma lipids and inflammation, increased the mitochondrial copy number, and led to a redistribution of mitochondria from a punctate to a more reticular pattern as observed in NGT. This was accompanied by disproportionately increased abundances of mitochondrial proteins, including those involved in fat oxidation and triglyceride synthesis. Pioglitazone also increased the abundance of collagen VI and decreased the abundance of cytoskeletal proteins. NADH cytochrome c reductase activity of isolated adipocyte mitochondria was similar in AGT and NGT and unaltered by pioglitazone. CONCLUSIONS: Adipocyte mitochondria are deficient in insulin-resistant individuals and correlate with systemic lipid metabolism, inflammation and insulin sensitivity. Pioglitazone induces mitochondrial biogenesis and reorganization as well as the synthesis of mitochondrial proteins including those critical for lipid metabolism. It also alters extracellular matrix and cytoskeletal proteins. The intrinsic function of adipocyte mitochondria appears unaffected in insulin resistance and by pioglitazone.International Journal of Obesity advance online publication, 31 October 2017; doi:10.1038/ijo.2017.192.
BACKGROUND/ OBJECTIVES: To gain further insight into the role of adipocyte mitochondria in systemic lipid metabolism, inflammation and insulin sensitivity in humans and to provide a better understanding of the mechanisms of action of the peroxisome proliferator-activated receptor gamma agonist pioglitazone. SUBJECTS/ METHODS: Mitochondrial DNA (mtDNA) copy number, mitochondrial distribution, mitochondrial and overall cellular protein abundances as well as intrinsic mitochondrial function of subcutaneous adipocytes were assessed by real-time quantitative PCR, MitoTracker staining, global proteomics analyses and NADH cytochrome c reductase activity in insulin-sensitive, normal-glucose-tolerant (NGT) individuals and age, gender, adiposity-matched insulin-resistant individuals with abnormal glucose tolerant (AGT) before and after 3 months of pioglitazone treatment. RESULTS: mtDNA copy number/adipocyte and mtDNA copy number/adipocyte volume were ~55% and ~4-fold lower in AGT than in NGT, respectively, and correlated positively with the M-value of euglycemic clamps and high-density lipoprotein, and negatively with fasting plasma triglyceride, tumor necrosis factor-α and interleukin-6 levels in the entire cohort. mtDNA copy number/adipocyte volume also correlated positively with plasma adiponectin. Pioglitazone, which improved insulin sensitivity, plasma lipids and inflammation, increased the mitochondrial copy number, and led to a redistribution of mitochondria from a punctate to a more reticular pattern as observed in NGT. This was accompanied by disproportionately increased abundances of mitochondrial proteins, including those involved in fat oxidation and triglyceride synthesis. Pioglitazone also increased the abundance of collagen VI and decreased the abundance of cytoskeletal proteins. NADH cytochrome c reductase activity of isolated adipocyte mitochondria was similar in AGT and NGT and unaltered by pioglitazone. CONCLUSIONS: Adipocyte mitochondria are deficient in insulin-resistant individuals and correlate with systemic lipid metabolism, inflammation and insulin sensitivity. Pioglitazone induces mitochondrial biogenesis and reorganization as well as the synthesis of mitochondrial proteins including those critical for lipid metabolism. It also alters extracellular matrix and cytoskeletal proteins. The intrinsic function of adipocyte mitochondria appears unaffected in insulin resistance and by pioglitazone.International Journal of Obesity advance online publication, 31 October 2017; doi:10.1038/ijo.2017.192.
Authors: Fedik Rahimov; Oliver D King; Doris G Leung; Genila M Bibat; Charles P Emerson; Louis M Kunkel; Kathryn R Wagner Journal: Proc Natl Acad Sci U S A Date: 2012-09-17 Impact factor: 11.205
Authors: H-J Choo; J-H Kim; O-B Kwon; C S Lee; J Y Mun; S S Han; Y-S Yoon; G Yoon; K-M Choi; Y-G Ko Journal: Diabetologia Date: 2006-02-25 Impact factor: 10.122
Authors: Rajesh R Rao; Jonathan Z Long; James P White; Katrin J Svensson; Jesse Lou; Isha Lokurkar; Mark P Jedrychowski; Jorge L Ruas; Christiane D Wrann; James C Lo; Donny M Camera; Jenn Lachey; Steven Gygi; Jasbir Seehra; John A Hawley; Bruce M Spiegelman Journal: Cell Date: 2014-06-05 Impact factor: 41.582
Authors: Leanne Wilson-Fritch; Sarah Nicoloro; My Chouinard; Mitchell A Lazar; Patricia C Chui; John Leszyk; Juerg Straubhaar; Michael P Czech; Silvia Corvera Journal: J Clin Invest Date: 2004-11 Impact factor: 14.808
Authors: Natalie Lefort; Brian Glancy; Benjamin Bowen; Wayne T Willis; Zachary Bailowitz; Elena A De Filippis; Colleen Brophy; Christian Meyer; Kurt Højlund; Zhengping Yi; Lawrence J Mandarino Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: Christian Setz; Maximilian Große; Janina Auth; Maria Fröba; Pia Rauch; Alexander Bausch; Matthew Wright; Ulrich Schubert Journal: Int J Mol Sci Date: 2022-06-20 Impact factor: 6.208
Authors: Lu Liu; Nitin Puri; Marco Raffaele; Joseph Schragenheim; Shailendra P Singh; J Alyce Bradbury; Lars Bellner; Luca Vanella; Darryl C Zeldin; Jian Cao; Nader G Abraham Journal: Prostaglandins Other Lipid Mediat Date: 2018-07-21 Impact factor: 3.072
Authors: Juan P Palavicini; Alberto Chavez-Velazquez; Marcel Fourcaudot; Devjit Tripathy; Meixia Pan; Luke Norton; Ralph A DeFronzo; Christopher E Shannon Journal: Front Physiol Date: 2021-12-02 Impact factor: 4.566
Authors: Bárbara María Varela-Rodríguez; Paula Juiz-Valiña; Luis Varela; Elena Outeiriño-Blanco; Susana Belén Bravo; María Jesús García-Brao; Enrique Mena; José Francisco Noguera; Javier Valero-Gasalla; Fernando Cordido; Susana Sangiao-Alvarellos Journal: J Clin Med Date: 2020-01-13 Impact factor: 4.241